{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:34:49Z","timestamp":1784918089590,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":2129,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.7861\/clinmedicine.18-3-212","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T10:05:18Z","timestamp":1527847518000},"page":"212-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians"],"prefix":"10.1016","volume":"18","author":[{"given":"Apostolos","family":"Koffas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E","family":"Dolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick TF","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.18-3-212_bib1","series-title":"Hepatitis B epidemiology in London: 2012 data","year":"2014"},{"key":"10.7861\/clinmedicine.18-3-212_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7861\/clinmedicine.15-2-191","article-title":"New insights in the management of chronic hepatitis B","volume":"15","author":"Gill","year":"2015","journal-title":"Clin Med"},{"key":"10.7861\/clinmedicine.18-3-212_bib3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.7861\/clinmedicine.18-3-212_bib4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28025","article-title":"Present and future therapies of hepatitis B: From discovery to cure","volume":"62","author":"Liang","year":"2015","journal-title":"Hepatology"},{"key":"10.7861\/clinmedicine.18-3-212_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4254\/wjh.v8.i8.385","article-title":"Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations","volume":"8","author":"Bessone","year":"2016","journal-title":"World J Hepatol"},{"key":"10.7861\/clinmedicine.18-3-212_bib6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ajt.12649","article-title":"Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation","volume":"14","author":"Martin","year":"2014","journal-title":"Am J Transplant"},{"key":"10.7861\/clinmedicine.18-3-212_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.7861\/clinmedicine.18-3-212_bib8","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1136\/bmj.f3893","article-title":"Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance","volume":"346","author":"Sarri","year":"2013","journal-title":"BMJ"},{"key":"10.7861\/clinmedicine.18-3-212_bib9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/MEG.0000000000000689","article-title":"Improving testing for hepatitis B before treatment with rituximab","volume":"28","author":"Dyson","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.7861\/clinmedicine.18-3-212_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.2010-0182","article-title":"An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening","volume":"16","author":"Leung","year":"2011","journal-title":"Oncologist"},{"key":"10.7861\/clinmedicine.18-3-212_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.7861\/clinmedicine.18-3-212_bib12","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/ajg.2017.397","article-title":"Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues","volume":"112","author":"Wu","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.7861\/clinmedicine.18-3-212_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jmv.24942","article-title":"Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA","volume":"90","author":"Anastasiou","year":"2018","journal-title":"J Med Virol"},{"key":"10.7861\/clinmedicine.18-3-212_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"10.7861\/clinmedicine.18-3-212_bib15","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.7861\/clinmedicine.18-3-212_bib16","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/cncr.30729","article-title":"Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy","volume":"123","author":"Hwang","year":"2017","journal-title":"Cancer"},{"key":"10.7861\/clinmedicine.18-3-212_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.7861\/clinmedicine.18-3-212_bib18","doi-asserted-by":"crossref","unstructured":"18 Rubin LG, Levin MJ, Ljungman P, et al 2013 IDSA clinical \u00adpractice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44\u2013100.","DOI":"10.1093\/cid\/cit684"},{"key":"10.7861\/clinmedicine.18-3-212_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/ciw222","article-title":"Transmission of hepatitis B core antibody and galactomannan enzyme immunoassay positivity via immunoglobulin products: a comprehensive analysis","volume":"63","author":"Ramsay","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmedicine.18-3-212_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.7861\/clinmedicine.18-3-212_bib21","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-015-2447-3","article-title":"Antiviral \u00adprophylaxis in patients with solid tumours and haematological malignancies\u2013update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"94","author":"Sandherr","year":"2015","journal-title":"Ann Hematol"},{"key":"10.7861\/clinmedicine.18-3-212_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.7861\/clinmedicine.18-3-212_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.7861\/clinmedicine.18-3-212_bib24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jmv.24423","article-title":"High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin\u2019s lymphoma","volume":"88","author":"Cho","year":"2016","journal-title":"J Med Virol"},{"key":"10.7861\/clinmedicine.18-3-212_bib25","first-page":"6543","article-title":"The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection","volume":"14","author":"Matsubara","year":"2017","journal-title":"Oncol Lett"},{"key":"10.7861\/clinmedicine.18-3-212_bib26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","article-title":"Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities","volume":"117","author":"Marcucci","year":"2011","journal-title":"Blood"},{"key":"10.7861\/clinmedicine.18-3-212_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/hepr.12603","article-title":"Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies","volume":"46","author":"Han","year":"2016","journal-title":"Hepatol Res"},{"key":"10.7861\/clinmedicine.18-3-212_bib28","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: Increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.18-3-212_bib29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12802","article-title":"Eighteen-month-lamivudine-prophylaxis on preventing occult hepatitis b virus (hbv) infection reactivation in patients with hematologic malignancies receiving immunosuppression therapy","volume":"25","author":"Marrone","year":"2018","journal-title":"J Viral Hepat"},{"issue":"9","key":"10.7861\/clinmedicine.18-3-212_bib30","doi-asserted-by":"crossref","first-page":"0184550","DOI":"10.1371\/journal.pone.0184550","article-title":"Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study","volume":"12","author":"Buti","year":"2017","journal-title":"PLoS ONE"},{"key":"10.7861\/clinmedicine.18-3-212_bib31","unstructured":"31 Potential risk of hepatitis B reactivation after treatment with BCR-ABL Tyrosine Kinase Inhibitors 2016. www.esmo.org\/Oncology-News\/Potential-Risk-of-Hepatitis-B-Reactivation-After-Treatment-With-BCR-ABL-Tyrosine-Kinase-Inhibitors, [Accessed 7 February 2017]."},{"key":"10.7861\/clinmedicine.18-3-212_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hammond","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.7861\/clinmedicine.18-3-212_bib33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"10.7861\/clinmedicine.18-3-212_bib34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cgh.2009.06.027","article-title":"Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression","volume":"7","author":"Palmore","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.7861\/clinmedicine.18-3-212_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11901-014-0238-2","article-title":"Immunosuppression in patients with chronic hepatitis B","volume":"13","author":"Seetharam","year":"2014","journal-title":"Curr Hepatol Rep"},{"key":"10.7861\/clinmedicine.18-3-212_bib36","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","article-title":"Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy","volume":"17","author":"Manzano-Alonso","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.7861\/clinmedicine.18-3-212_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cld.413","article-title":"Medical interventions associated with HBV reactivation: common and less common","volume":"5","author":"Reynolds","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.7861\/clinmedicine.18-3-212_bib38","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.7861\/clinmedicine.18-3-212_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1756-185X.12154","article-title":"Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs","volume":"16","author":"Lee","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.7861\/clinmedicine.18-3-212_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5045\/br.2015.50.1.51","article-title":"HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT","volume":"50","author":"Gu","year":"2015","journal-title":"Blood Res"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182401707X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182401707X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.18-3-212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:34:37Z","timestamp":1761460477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147021182401707X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S147021182401707X"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.18-3-212","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.18-3-212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2018. All rights reserved.","name":"copyright","label":"Copyright"}]}}